Biogen Inc. Insider Trading

BIIB

⊜ Compare

Last 12 months

Insiders bought $585 and sold 905K on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−905K

1 buy · 3 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

1 / 2

executives and directors

Last open-market buy

Feb 2026

Feb 12, 2026

Get an email when BIIB's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 3 – 4	Lloyd Minor Director	Sold10b5-1 plan 2 parts	1,186	$202.15 average	240K	31%	Form 4
Feb 12	Nicole Murphy Head of Pharm Ops and Tech	Bought	3	$195.04	$585	<0.1%	Form 4
Feb 9	Priya Singhal Head of Development	Sold10b5-1 plan	2,660	$199.83	532K	25%	Form 4
Feb 2	Priya Singhal Head of Development	Sold10b5-1 plan	748	$179.30	134K	11%	Form 4
Sep 2, 2025	Priya Singhal Head of Development	Sold10b5-1 plan	517	$133.55	69K	8.2%	Form 4
Jul 8, 2025	Rachid Izzar Head of Global Product Strat.	Sold10b5-1 plan	2,223	$135.00	300K	26%	Form 4
May 19, 2025	Priya Singhal Head of Development	Sold10b5-1 plan	3,806	$126.25	481K	41%	Form 4
May 2, 2025	Caroline Dorsa Director	Bought	1,235	$122.72	152K	4.6%	Form 4
Mar 7, 2025	Stephen A Sherwin Director	Sold10b5-1 plan	8,760	$150.02	$1.31M	44%	Form 4
Dec 9, 2024	Priya Singhal Head of Development	Sold10b5-1 plan	110	$157.21	17K	2.0%	Form 4

Aug 3 – 410b5-1 plan
Lloyd Minor
Director · sold 1,186 at avg $202.15
240K
31% of stake
Feb 12
Nicole Murphy
Head of Pharm Ops and Tech · bought 3 at $195.04
$585
<0.1% of stake
Feb 910b5-1 plan
Priya Singhal
Head of Development · sold 2,660 at $199.83
532K
25% of stake
Feb 210b5-1 plan
Priya Singhal
Head of Development · sold 748 at $179.30
134K
11% of stake
Sep 2, 202510b5-1 plan
Priya Singhal
Head of Development · sold 517 at $133.55
69K
8.2% of stake
Jul 8, 202510b5-1 plan
Rachid Izzar
Head of Global Product Strat. · sold 2,223 at $135.00
300K
26% of stake
May 19, 202510b5-1 plan
Priya Singhal
Head of Development · sold 3,806 at $126.25
481K
41% of stake
May 2, 2025
Caroline Dorsa
Director · bought 1,235 at $122.72
152K
4.6% of stake
Mar 7, 202510b5-1 plan
Stephen A Sherwin
Director · sold 8,760 at $150.02
$1.31M
44% of stake
Dec 9, 202410b5-1 plan
Priya Singhal
Head of Development · sold 110 at $157.21
17K
2.0% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BIIB, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with BIIB

CompareIntrinsic value

NBIXNeurocrine Biosciences Inc.

$167.21+1.43%85

EXELExelixis Inc.

$72.75+0.61%97

MRNAModerna, Inc.

$258.31+13.08%20

HALOHalozyme Therapeutics Inc.

$130.34+1.34%66

TECHBio-Techne Corporation

$72.73+0.10%52

GILDGilead Sciences Inc.

$174.49+4.19%48

AMGNAmgen Inc.

$478.48+3.73%45

BHCBausch Health Companies Inc.

$8.34+2.46%56

Held by ETFs

BIIB is in 307 US ETFs. The largest of them, with BIIB's weight in each:

Spot a number that looks wrong? Check it in BIIB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BIIB

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.